DNAIn an new article via PharmaVoice.com, “For most of the pharmaceutical industry, the focus on patient centricity is a relatively new phenomenon, and the industry continues to shift its focus to include patients as stakeholders when planning its marketing strategies, clinical trials, and R&D strategies…Our experts say patient networks and advocacy groups greatly influence rare disease research and development, clinical trials, regulations, and marketing efforts.”  For more information on how patients influence rare disease therapies, please visit: http://www.pharmavoice.com/article/2016-02-rare-disease-therapies/